Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 345

Sort by

Sort Order Select

Journal Articles

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke, Sabrina Kraus, Armin Ehninger, Ralf C. Bargou, Maria-Elisabeth Goebeler, Jan Moritz Middeke, Carla Kreissig, Malte von Bonin, Jan Koedam, Michael Pehl, Martin Bornhäuser, Hermann Einsele, Gerhard Ehninger, Marc Cartellieri

Blood (2021) 137 (22): 3145–3148.

https://doi.org/10.1182/blood.2020009759

Published: 2021

Journal Articles

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo M odels of Cohesin-Mutant Myeloid Diseases

Mounica Vallurupalli, MD, Rebecca Gorelov, BS, Jacqueline S Garcia, MD, Elizabeth A Morgan, MD, Benjamin Ebert, MD, Zuzana Tothova, MD PhD

Blood (2019) 134 (Supplement_1): 560.

https://doi.org/10.1182/blood-2019-130308

Published: 2019

Journal Articles

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

James Aries, Sarah Charrot, Jennifer Ball, Matthew Mee, Symeon Theocharidis, Sofie Van Gassen, Sameena Iqbal, John G. Gribben, MD DSc, Jeff Davies, MBBS, PhD

Blood (2019) 134 (Supplement_1): 595.

https://doi.org/10.1182/blood-2019-124875

Published: 2019

Journal Articles

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Konstantinos Tzelepis, Etienne De Braekeleer, PhD MSc, Eliza Yankova, PhD, Justyna Rak, PhD, Demetrios Aspris, MSc, Ana Filipa Domingues, PhD, Richard Fosbeary, Alan Hendrick, PhD, Dan Leggate, PhD, Yaara Ofir-Rosenfeld, PhD, Alexandra Sapetschnig, PhD, Cristina Pina, MDDPhil, Mark Albertella, PhD, Wesley Blackaby, PhD, Oliver Rausch, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Tony Kouzarides, PhD

Blood (2019) 134 (Supplement_1): 403.

https://doi.org/10.1182/blood-2019-127962

Published: 2019

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Blood (2019) 134 (Supplement_1): 610.

https://doi.org/10.1182/blood-2019-125968

Published: 2019

Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 670.

https://doi.org/10.1182/blood-2019-127119

Published: 2019

Journal Articles

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Karen Dybkær, PhD, Hanne Due, MSc, Rasmus Froberg Brøndum, PhD, Ken H. Young, MD PhD, Martin Bøgsted, PhD

Blood (2019) 134 (Supplement_1): 1623.

https://doi.org/10.1182/blood-2019-122351

Published: 2019

Journal Articles

In Human Visualization of Ibrutinib-Induced CLL Compartment Shift

Marius E Mayerhoefer, Alexander Haug, Ulrich Jaeger, MD, Lukas Kazianka, MD, Verena Pichler, Sarah Pfaff, Hans-Jürgen Wester, PhD, Marcus Hacker, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 1750.

https://doi.org/10.1182/blood-2019-131469

Published: 2019

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

Proof of Concept for Repair of Sickle Cell Disease By Non-Myeloablative MHC Disparate T Cell Depleted HSCT Combined with Donor-Derived Veto Cells

Aloukick Kumar Singh, PhD, Elias Schetzen, PhD, Esther BACHAR Lustig, PhD, Wei-Hsin Liu, M.Sc, Raj Kumar Yadav, PhD, Sandeep Kumar Yadav, PhD, Kathryn McGinnis, M.Sc, Yair Reisner, PhD

Blood (2019) 134 (Supplement_1): 1919.

https://doi.org/10.1182/blood-2019-124594

Published: 2019

Journal Articles

Enabling Gene-Edited, Regulatory-like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders

Yuchi Honaker, PhD, Karen Sommer, PhD, Noelle Dahl, Yufei Xiang, MD, PhD, Christina Lopez, PhD, Samuel Scharffenberger, Michelle Christian, Troy R. Torgerson, MD PhD, Andrew M. Scharenberg, MD, David J. Rawlings, MD

Blood (2019) 134 (Supplement_1): 2071.

https://doi.org/10.1182/blood-2019-131946

Published: 2019

Journal Articles

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Mahmoud Hallal, BSc, MSc, Sophie Braga-Lagache, MSc, Jovana Jankovic, Rémy Bruggmann, PhD, Ramanjaneyulu Allam, PhD MSc, BSc, Mario P. Tschan, PhD, Cédric Simillion, PhD, Manfred Heller, PhD, Nicolas Bonadies, MD

Blood (2019) 134 (Supplement_1): 2079.

https://doi.org/10.1182/blood-2019-122337

Published: 2019

Journal Articles

Automation Platform for CAR-T Manufacturing: The Benefits and the Clinical Outcomes

Min Wang, PhD, Fengtao You, PhD, Xingbing Wang, MD, Bingzong Li, MD PhD, Hanying Xu, MS, Yu Wang, MS, Guifang Pan, MS, Song Sun, MS, Huimin Meng, MD PhD, Yanmei Zhao, MS, Yu-Sheng Chen, PhD, Bozhen Zhang, MBA, Lin Yang, PhD

Blood (2019) 134 (Supplement_1): 1960.

https://doi.org/10.1182/blood-2019-123656

Published: 2019

Journal Articles

Analyzing the Efficacy and Design Considerations of VR Environments to Manage Anxiety & Depression in AYA Cancer Patients

Elizabeth H. Cull, MD, Aniket Saha, MD MS, Laura Michelle Stanley, PhD, Vishnunarayan Prabhu, MS, Joshua Biro

Blood (2019) 134 (Supplement_1): 3441.

https://doi.org/10.1182/blood-2019-128201

Published: 2019

Journal Articles

Development of a Personalized 3D Carotid Model for Cerebral Vasculopathy Monitoring in Sickle Cell Disease

Nguyen-Peyre Kim-Anh, PhD, Laurène Lenoir, Valentin Amar, Frédéric Segonds, Nuriye Akçay, Seguin Marion, Philippe Connes, PhD, France Pirenne, MD PhD, Jean-Frédéric Gerbeau, Irène Vignon-Clémentel, Suzanne Verlhac, MD, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 3570.

https://doi.org/10.1182/blood-2019-124327

Published: 2019

Journal Articles

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Antonio M. Risitano, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Rosario Notaro, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Jong-Wook Lee, MD, Mingjun Huang, PhD, Michael Geffner, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 3514.

https://doi.org/10.1182/blood-2019-124748

Published: 2019

Journal Articles

Development of a Low-Cost Electrical Impedance-Based Microflow Cytometer

Darryl Dieujuste, BS,MS, Jia Liu, E. Du, PhD, Ofelia A. Alvarez, MD

Blood (2019) 134 (Supplement_1): 4665.

https://doi.org/10.1182/blood-2019-129068

Published: 2019

Journal Articles

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

Jevgenia Zilberman-Rudenko, Hiroshi Deguchi, MD PhD, Mohammed Hayat, Meenal Shukla, PhD, Jennifer Nagrampa Orje, Zihan Guo, Tine Wyseure, PhD, Laurent O Mosnier, Owen J T McCarty, PhD, Zaverio M. Ruggeri, MD, John H. Griffin, PhD

Blood (2019) 134 (Supplement_1): 3632.

https://doi.org/10.1182/blood-2019-129312

Published: 2019

NARROW

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo M odels of Cohesin-Mutant Myeloid Diseases

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

In Human Visualization of Ibrutinib-Induced CLL Compartment Shift

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Proof of Concept for Repair of Sickle Cell Disease By Non-Myeloablative MHC Disparate T Cell Depleted HSCT Combined with Donor-Derived Veto Cells

Enabling Gene-Edited, Regulatory-like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Automation Platform for CAR-T Manufacturing: The Benefits and the Clinical Outcomes

Analyzing the Efficacy and Design Considerations of VR Environments to Manage Anxiety & Depression in AYA Cancer Patients

Development of a Personalized 3D Carotid Model for Cerebral Vasculopathy Monitoring in Sickle Cell Disease

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Development of a Low-Cost Electrical Impedance-Based Microflow Cytometer

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only